Kcnh7-KO Mouse
一般名
Kcnh7-KO
製品ID
S-KO-02976
背景情報
C57BL/6JCya
系統ID
KOCMP-170738-Kcnh7-B6J-VA
状況
このマウス系統を論文で使用する場合は、「Kcnh7-KO Mouse(カタログ番号S-KO-02976)はサイアジェンから購入しました。」と引用してください。
製品タイプ
年齢
遺伝子型
性別
数量
標準的な配送方法では、少なくとも3匹のヘテロ接合体キャリアを保証しています。ホモ接合体キャリアや指定された性別の個体の繁殖サービスも利用可能です。
基本情報
系統名
Kcnh7-KO
系統ID
KOCMP-170738-Kcnh7-B6J-VA
遺伝子名
製品ID
S-KO-02976
遺伝子別名
erg3, Kv11.3, 9330137I11Rik
遺伝子別名
C57BL/6JCya
NCBI ID
修正
Conventional knockout
染色体
Chr 2
表現型
アプリケーション
--
さらに
系統詳細
EnsemblトランスクリプトID
ENSMUST00000075052
NCBIトランスクリプトID
NM_133207
ターゲット領域
Exon 5~6
有効領域の大きさ
~10.4 kb
遺伝子研究の概要
Kcnh7, also known as erg3 (ether-à-go-go-related gene 3), is a member of the voltage-gated K+ channel Kv11 family. Potassium channels are crucial for stabilizing the resting potential and neuronal excitability. Kcnh7 channels play a role in dampening spontaneous activity in cerebellar Purkinje cells (PCs) and hippocampal CA1 neurons, thus regulating neuronal excitability [5].
In a study on schizophrenia, SNPs in Kcnh7 were associated with patients' responses to risperidone treatment. Specifically, the rs77699177 (C > T) in the Kcnh7 gene intron and rs2241240 SNP were significantly associated with treatment responses, indicating its potential as a functional marker for predicting treatment efficacy in schizophrenia [1]. In bipolar spectrum disorder, a non-synonymous variant of Kcnh7 (c.1181G>A, p.Arg394His) was found to be associated with the disorder. The variant altered the steady-state voltage dependence and kinetics of activation in neuronal cells, suggesting its involvement in the pathophysiology of bipolar spectrum disorder [3]. Whole exome sequencing also identified Kcnh7 variants associated with epilepsy in children [4]. In glioblastoma, Kcnh7 was identified as a potential factor associated with the proliferation of malignant cells, indicating its role in this aggressive brain tumor [2].
In conclusion, Kcnh7 is an important voltage-gated potassium channel gene involved in regulating neuronal excitability. Studies using genetic association analysis in humans have revealed its potential roles in diseases such as schizophrenia, bipolar spectrum disorder, epilepsy, and glioblastoma. These findings contribute to understanding the pathophysiology of these diseases and may potentially lead to the development of novel therapeutic strategies targeting Kcnh7.
References:
1. Wang, Xueping, Su, Yi, Yan, Hao, Huang, Yu, Yue, Weihua. 2019. Association Study of KCNH7 Polymorphisms and Individual Responses to Risperidone Treatment in Schizophrenia. In Frontiers in psychiatry, 10, 633. doi:10.3389/fpsyt.2019.00633. https://pubmed.ncbi.nlm.nih.gov/31543842/
2. Wang, Liping, Li, Xinyi, Xu, Chengshi, Li, Yirong, Li, Zhiqiang. 2024. Unveiling novel cell clusters and biomarkers in glioblastoma and its peritumoral microenvironment at the single-cell perspective. In Journal of translational medicine, 22, 551. doi:10.1186/s12967-024-05313-5. https://pubmed.ncbi.nlm.nih.gov/38851695/
3. Strauss, Kevin A, Markx, Sander, Georgi, Benjamin, Bucan, Maja, Puffenberger, Erik G. 2014. A population-based study of KCNH7 p.Arg394His and bipolar spectrum disorder. In Human molecular genetics, 23, 6395-406. doi:10.1093/hmg/ddu335. https://pubmed.ncbi.nlm.nih.gov/24986916/
4. Wu, Fan, Ji, Xinna, Shen, Mengxiao, Zhang, Xue, Chen, Qian. 2024. Whole exome sequencing identifies KCNH7 variants associated with epilepsy in children. In Genes & diseases, 12, 101322. doi:10.1016/j.gendis.2024.101322. https://pubmed.ncbi.nlm.nih.gov/39634124/
5. Schwarz, Jürgen R, Freitag, Sandra, Pechmann, Yvonne, Hornig, Sönke, Kneussel, Matthias. 2024. Purkinje cell hyperexcitability and depressive-like behavior in mice lacking erg3 (ether-à-go-go-related gene) K+ channel subunits. In Science advances, 10, eadn6836. doi:10.1126/sciadv.adn6836. https://pubmed.ncbi.nlm.nih.gov/39365861/
品質管理基準
精子検査
凍結前の精子濃度を測定し、精子の生存能力の判定します。
凍結後の精子では、各バッチから1本の凍結保存された精子を選び出し、体外受精に使用します。
環境基準:
SPF対応地域:
グローバル由来:
Cyagenお問い合わせ
カスタムの動物モデルに関するご相談は、下記のフォームにご記入いただき、ご連絡いただくか見積もりをご依頼ください。
Cyagenはお客様のプライバシーを大変重視しています。当社の最新の製品や情報をお届けしたいと思っています。お客様の設定をご確認ください。
これらの配信はいつでも解除できます。配信停止方法およびデータ保護の詳細は プライバシーポリシー をご確認ください。
以下のボタンをクリックすることで、このフォームにご入力いただいた個人情報をCyagenが保存・処理し、ご要望のコンテンツを提供することに同意されたことになります。
